Sjuts Dustin S 4
4 · Revance Therapeutics, Inc. · Filed Feb 2, 2023
Insider Transaction Report
Form 4
Sjuts Dustin S
Chief Commercial Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2023-01-31+43,255→ 43,255 totalExercise: $34.68Exp: 2033-01-30→ Common Stock (43,255 underlying)
Footnotes (1)
- [F1]The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 31, 2023, subject to Mr. Sjuts' Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.